Navigation Links
Leading Researchers in Vision Impairment and Blindness to Present at EURETINA Winter Meeting
Date:2/1/2013

ROME, Feb. 1, 2013 /PRNewswire/ -- Retina Implant AG, the leading developer of subretinal implants for patients blinded by retinitis pigmentosa (RP), and Okuvision GmbH, an innovator in the field of transcorneal electrical stimulation (TES) therapy for early and intermediate stage RP patients, today announced that research on both companies' devices will be presented at the EURETINA Winter Meeting in Rome, Italy, February 1-3. Sister companies, Retina Implant and Okuvision have developed breakthrough medical devices that aim to provide in-need RP patients with new tools to combat total blindness or the onset of blindness. Research and findings will be presented by global experts in the field of ophthalmology, including: Katarina Stingl , M.D., clinical scientist and consultant ophthalmologist, Institute for Ophthalmic Research at the Centre for Ophthalmology of the University of Tuebingen, Germany; Andreas Schatz , M.D., resident and fellow at the University Eye Hospital and Institute for Ophthalmic Research at the Centre for Ophthalmology, University of Tuebingen, Germany; and Professor Robert MacLaren , professor of Ophthalmology at the University of Oxford and a consultant retinal surgeon at the Oxford Eye Hospital, UK.

(Logo: http://photos.prnewswire.com/prnh/20130201/NE51162LOGO)

"We are thrilled to have our innovative technology presented to leading retinal specialists in Europe – we are confident our scientific research and clinical trial data will be of great interest to attendees and will expand the body of knowledge on retinal implants and visual results," said Walter-G. Wrobel , president and CEO of Retina Implant AG. "Last year Retina Implant researchers gained more experience working with implanted patients through the second human clinical trial, with the global total of implanted patients reaching 35. Importantly, we continue to learn more about how to best operate on and place the microchip in patients, and we are encouraged by the positive visual results some patients have reported, including the ability to read numbers on the side of dice."

Sessions on Retina Implant's Alpha IMS microchip and about Okuvision's TES are as follows:

  • Katarina Stingl , M.D. will speak in the Artificial Vision and Electrical Stimulation of the Eye session about Retina Implant's Alpha IMS microchip's clinical results on February 1, 16:00-18:00 CET.
  • Andreas Schatz , M.D. will also speak in the session on Artificial Vision and Electrical Stimulation of the Eye about transcorneal electrical stimulation (TES) and phosphene thresholds in healthy subjects and patients with retinal diseases on February 1, 16:00-18:00 CET.
  • Professor Robert MacLaren will present on restoring vision through Retina Implant's subretinal implant and the relevance to future stem cell therapies during the Regeneration/Degeneration session on Saturday, February 2, 8:30-10:30 CET.
  • Retina Implant's 3x3mm2, 1,500 electrode, subretinal implant has been in clinical trials since 2005. The microchip is designed to restore useful vision in patients blinded by RP and is implanted below the retina in the macular region. Published in Proceedings of the Royal Society B in 2010, results from the Company's first human clinical trial showed that placement of the implant below the retina provided optimum visual results, allowing patients to recognize foreign objects, as well as recognize letters to form words. Beginning in May 2010, the Company's second human clinical trial is currently underway in Germany, the UK and Hong Kong.

    Sister company Okuvision GmbH's OkuStim® technology received CE mark approval in 2011 for use as a treatment to help delay the progression of RP. The device consists of a frame worn on the patient's head and a hand-held stimulation controller that works by sending small amounts of current to stimulate the retina. Results of Okuvision's pilot study were published in April 2011 in Investigative Ophthalmology and Visual Science  and showed that patients receiving 150 percent stimulation showed a 20 percent statistically significant improvement in their field of vision. The Company recently launched two additional, post-market studies in Germany and other European countries to continue research on the OkuStim device.

    "Last year was a pivotal time for Okuvision, with the launch of two post-market studies on our OkuStim device and the beginning of patient enrolment throughout the EU and UK," said Reinhard Rubow , CEO, Okuvision GmbH. "With more information expected in the coming year on the ideal level of transcorneal electrical stimulation for patients with RP and its long-term effects, leaders in vision impairment are becoming increasingly eager to learn more about the potential benefits of the new therapy for earlier stage RP patients."

    For more information on the Retina Implant and Okuvision presentations at EURETINA's Winter Meeting in Rome, please visit the conference Website.

    About Retinitis Pigmentosa
    Retinitis pigmentosa (RP) is one of the most common forms of inherited retinal degenerations affecting 1 in every 3,000-4,000 people in Europe. A progressive condition that gets worse over time, RP typically causes severe vision problems in adulthood. Retinal implants represent tremendous promise for enabling RP patients to regain sight.

    About Retina Implant AG
    Retina Implant AG is the leading developer of subretinal implants for partially sighted and blind patients. After extensive research with German university hospitals and institutes which began with a large grant from the German Federal Ministry of Research and Education in 1996, Retina Implant AG was founded by Dr. Eberhart Zrenner and his colleagues in 2003 with private investors with the goal of developing a fully-functioning electronic retinal implant to restore useful vision to the blind. Retina Implant began implanting in human patients in 2005 and started a second clinical trial in 2010. To learn more, visit: http://www.retinaimplant.de/.

    About Okuvision GmbH
    Founded by the leaders of Retina Implant AG in 2007, Okuvision GmbH is an innovator in the field of transcorneal electrical stimulation (TES) for patients with early and intermediate stage retinitis pigmentosa. Building on the lessons learned through the use of Retina Implant AG's subretinal implant technology, Okuvision was founded with the goal of testing and developing a treatment option aimed at delaying the effects of retinitis pigmentosa. Okuvision's first study began in 2007 and treated 24 patients over a period of six weeks. To learn more, please visit: http://www.okuvision.de/en.Schwartz MSL:Retina Implant AG:Kirsten Fallon/Charlotte Webber

    Walter-G. WrobelU.S. Inquiries: 781-684-0770

    + 49 7121 36403-111 UK/EU Inquiries: +44 (0)7949 872296

    Wrobel@retina-implant.deRetinaImplant@SchwartzMSL.com Okuvision@SchwartzMSL.com Okuvision GmbH:Reinhard Rubow+49 7121 36403 100Reinhard.Rubow@okuvision.de


    '/>"/>
    SOURCE Retina Implant AG
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Leading Cardiologist Dispels the Myths about Dietary Supplement Niacin
    2. DenMat Announces Signing a Purchase Agreement to Acquire PeriOptix Inc., Leading Provider of Magnification and Illumination Technologies
    3. Drugs.com Releases Q3 Sales for Top 100 U.S. Drugs: Singulair Drops But Nexium and Abilify Remain the Leading Brands
    4. World Diagnostic Imaging Market Outlook and Leading Suppliers Business Strategies and Marketing Tactics
    5. Validus Pharmaceuticals Now Exclusively Marketing Six Established U.S. Product Lines Purchased From Leading Healthcare Company
    6. Optimal Radiology Partners with Leading Radiology Practice
    7. Frost & Sullivan Solidifies the Prominence of Leading Organizations through Best Practice Recognition
    8. Omeros Responds to Misleading Announcement by Davis Wright Tremaine Concerning Settlement with Former Chief Financial Officer
    9. 90 Presentations at Leading Radiation Oncology Meeting Demonstrate the Breadth and Depth of Clinical Evidence for Accuray Technologies
    10. LABSCO Implements Leading-Edge Technology to Support Growth and Seize Opportunities in the Clinical Laboratory Market
    11. Presentations at Leading Radiation Oncology Meeting Highlight CyberKnife Prostate Outcomes from Patients at More Than 40 Centers
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/8/2016)... , Feb. 8, 2016  Echo ... medical device company focused on non-invasive continuous ... announced today announced that it will host ... February 17, 2015 at 9:00 a.m. Eastern ... discuss its corporate strategy, advancements in its ...
    (Date:2/8/2016)... a historic vote among its members this weekend, the Shinnecock Indian Nation ... and dispensary on tribal land near Southampton . ... for patients in the state,s Medical Cannabis Program. --> ... in the state,s Medical Cannabis Program. --> Tribal members ... designation from the State of New York as ...
    (Date:2/8/2016)... , Switzerland and PALO ALTO, Calif. , ... biological and chemical manufacturing, and Kodiak Sciences Inc., a ... treatment of retinal disease, announced today agreements for the ... Lonza will manufacture material at multiple sites, including Slough ... --> --> Retinal diseases, such ...
    Breaking Medicine Technology:
    (Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... a wide variety of organizations. DocuSyst provides a cloud hosted environment for ... Some installations include integration with various 3rd party applications using the FileHold web ...
    (Date:2/8/2016)... ... February 08, 2016 , ... TopConsumerReviews.com recently awarded their highest ... products. , Moles are derived from a cluster of melanin when exposed to sunlight. ... places and create a lifetime of embarrassment. Historically, mole removal has involved ...
    (Date:2/8/2016)... ... February 08, 2016 , ... According to research ... U.S. require dental technicians to be certified or obtain continuing education. To increase ... the “What’s In Your Mouth?” campaign to inform dentists and patients about the ...
    (Date:2/7/2016)... ... February 07, 2016 , ... ... Plastics, has added Kybella® to his medical and surgical expertise. Technically known as ... FDA injectable medication used as a non-surgical alternative for reduction of fat below ...
    (Date:2/6/2016)... ... ... Shark Finds and Kevin Harrington, along with the Product Managers ... Belly Bands. , Having a dog is great—except when it wets every couch, bed, ... works, get Belly Bands, the easiest way to stop dogs from wetting on ...
    Breaking Medicine News(10 mins):